Sunday, September 6

Browsing: LY4064809

Treatments

98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1

By NewsCancerMay 22, 20260

BackgroundPI3Kα inhibitors (PI3Kαi) demonstrated clinical benefit in approximately 40% of patients with hormone receptor–positive/HER2-negative (HR+/HER2–) advanced breast cancer with PIK3CA…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab

A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions

Browsing: LY4064809

98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab

A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions

How Might WCLC 2026 Clarify the Evolving Role of APPs in Lung Cancer?

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab

A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions

How Might WCLC 2026 Clarify the Evolving Role of APPs in Lung Cancer?

Latest Post

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab

A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions

Subscribe to Updates

What's Hot

Browsing: LY4064809